New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
16:22 EDTIGIGI Laboratories director Damian Finio resigns
IGI Laboratories has accepted Damian Finio's resignation from its Board of Directors effective August 11. Mr. Finio has accepted a senior level finance position at a pharmaceutical company, and will be unable to continue in his role as Director. The company has begun a search to replace Mr. Finio on its Board.
News For IG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
10:00 EDTIGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:31 EDTIGIGI Laboratories upgraded to Buy with $11 target at Roth Capital
Subscribe for More Information
06:14 EDTIGIGI Laboratories upgraded to Buy from Neutral at Roth Capital
July 23, 2015
19:06 EDTIGOn The Fly: After Hours Movers
UP AFTER EARNINGS: Amazon (AMZN), up 17.2%... Marketo (MKTO), up 15.4%... Juniper Networks (JNPR), up 9.9%... NetGear (NTGR), up 9.2%... Qlik Technologies (QLIK), up 9.1%... LogMeIn (LOGM), up 9.9%... Pandora (P), up 10.3%... Mitek Systems (MITK), up 7.8%... Proofpoint (PFPT), up 5.1%... Supreme Industries (STS), up 4.7%... Skyworks (SWKS), up 3.6%... IGI Laboratories (IG), up 3.7%... Maxim Integrated Products (MXIM), up 4.1%... Boyd Gaming (BYD), up 4.1%... Trinity Industries (TRN), up 5%... Trinity Industries (N), up 3.2%... Starbucks (SBUX), up 4.5%. ALSO HIGHER: Qorvo (QRVO), up 2.7% after Skyworks reported quarterly results. DOWN AFTER EARNINGS: TrueCar (TRUE), down 33.1% after reporting quarterly results and cutting fiscal 2015 revenue guidance... Tripadvisor (TRIP), down 9.2%... Align Technology (ALGN), down 7.4%... Capital One (COF), down 4.9%... PMC-Sierra (PMCS), down 9.1%... athenahealth (ATHN), down 2.1%. ALSO LOWER: Sunesis Pharmaceuticals (SNSS), down 59.7% after giving vosaroxin regulatory update... Avalanche Biotechnologies (AAVL), down 5.6% after CEO Thomas Chalberg, Jr., Ph.D. resigns and Hans Hull name interim CEO.
16:38 EDTIGIGI Laboratories sees FY15 revenue $35M-$40M, consensus $38.49M
Subscribe for More Information
16:37 EDTIGIGI Laboratories reports Q2 adjusted EPS (4c), consensus (8c)
Reports Q2 revenue $8.9M, consensus $7.63M.
16:10 EDTIGIGI Laboratories submits sixth ANDA of 2015
IGI Laboratories has submitted its sixth abbreviated new drug application to the FDA of 2015, which brings the company's total number of ANDA submissions now pending at the FDA to twenty-eight.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use